Bone News and Research

RSS

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

AstraZeneca and Rigel Pharmaceuticals today announced an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational product for rheumatoid arthritis (RA) and additional indications.

16 Feb 2010

Bone-anchored hearing aids appear to be durable treatment option for single-sided deafness

Surgically implanted hearing aids anchored to the skull bone appear to be a durable treatment option that noticeably improves hearing among children with deafness in one ear, according to a report in the February issue of Archives of Otolaryngology -- Head & Neck Surgery, one of the JAMA/Archives journals.

16 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

Stematix enters into 10-year exclusive agreement with Laboratorios Bagó SA

Stematix, Inc. (Houston, USA), a regenerative medicine provider positioned to accelerate safe and effective global use of stem cell therapies, announced today that it entered into a 10-year exclusive agreement with Laboratorios Bagó (Buenos Aires, Argentina), a leading Argentine medical products company.

15 Feb 2010

Fast method for producing bone and cartilage tissue using body's own cells

Injuries to joints and cartilage can have serious consequences, including osteoarthritis. Cartilage degeneration in joints is a widespread disease in Germany and worldwide. Prof. Dr. Prasad Shastri is an expert in tissue engineering (TE), tissue construction and tissue cultivation using the body's own cells. He is Professor of Biofunctional Macromolecular Chemistry at the Centre for Biological Signalling Studies (BIOSS), a Cluster of Excellence at the University of Freiburg, where he has been researching for the last year.

15 Feb 2010

Bacterin International completes $3M private placement of Secured Convertible Promissory Notes

Bacterin International, Inc. (Bacterin), a developer of biological scaffolds for orthopedic indications, today announced the completion of a $3 million private placement of Secured Convertible Promissory Notes led by Middlebury Securities, LLC.

14 Feb 2010

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development.

14 Feb 2010

Glycotex announces the expansion of patent portfolio in Advanced Wound Healing for GLYC-101

Glycotex, Inc. today announced the expansion of its patent portfolio in Advanced Wound Healing for its product candidate GLYC-101 currently in clinical phase 2 in the United States.

12 Feb 2010

Better and standardized animal models needed for musculoskeletal regenerative medicine

Clinical testing and development of novel therapies based on advances in tissue engineering and regenerative medicine that will one day enable the repair and replacement of diseased or damaged human muscle, bone, tendons, and ligaments depends on the availability of good animal models.

12 Feb 2010

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation announced today two-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate (formerly Genz-112638). Continued improvements were observed across all endpoints, including bone disease, at the two-year timepoint, compared with baseline. The two-year results were presented for the first time today at the Lysosomal Disease Network WORLD Symposium in Miami, Fla.

12 Feb 2010

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire plc, the global specialty biopharmaceutical company, today presented positive results from its first Phase III study (TKT 032) evaluating safety and efficacy of velaglucerase alfa, its investigational enzyme replacement therapy for the treatment of Type 1 Gaucher disease. The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.

12 Feb 2010

RTI Biologics supports Haiti relief efforts with Matrix HD sterilized dermis allografts donation

RTI Biologics Inc., the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated Matrix HD™ sterilized dermis allografts to use in limb salvage procedures for victims of the recent natural disasters in Haiti.

12 Feb 2010

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Protalix BioTherapeutics, Inc., announced today that additional data from the Company's pivotal Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease was presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010 in Miami, Florida, during an oral session titled, "Novel Enzyme Replacement Therapy for Gaucher Disease: Phase III Pivotal Clinical Trial with Plant Cell Expressed Recombinant Glucocerebrosidase (prGCD) - taliglucerase alfa."

12 Feb 2010

Fourth-quarter and full-year 2009 results announced by Quidel

Quidel Corporation, a leading provider of rapid point-of-care diagnostic tests, announced today financial results for the fourth quarter and full year ended December 31, 2009.

12 Feb 2010

Corgenix Medical files second-quarter Form 10-Q and reports financial results ended December 31, 2009

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, today filed its 2nd quarter Form 10-Q and reported its financial results.

11 Feb 2010

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Daiichi Sankyo, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the hypertension treatment Benicar® (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age. Benicar was originally approved in 2002 for the treatment of hypertension in adults.

11 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Oral hygiene: Insights

Oral health is often the window to your overall health. Evidence has supported the link between poor oral health and such conditions as stroke, premature birth and diabetes. Other conditions, such as HIV/AIDS and osteoporosis may show preliminary signs in your mouth, before other areas of the body are affected. Also, some of your daily activities or habits can affect your oral health. Therefore, it's wise to pay attention to your teeth and gums.

11 Feb 2010

Micromet outlines the design of registration study for blinatumomab in ALL

At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S.

11 Feb 2010

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Elbit Imaging Ltd. announces that its associated company (approximately 28% holding on a fully diluted basis), Gamida Cell Ltd. ("Gamida Cell") through the Gamida-Teva Joint Venture (JV), announced today that the Data Monitoring Committee ("DMC") has independently reviewed preliminary data from the pivotal registration, Phase III clinical trial of StemEx (called ExCell) and has recommended that the JV continue to enroll patients in this study.

11 Feb 2010

Bone News and Research

AstraZeneca, Rigel Pharmaceuticals announce exclusive worldwide license agreement for R788

Bone-anchored hearing aids appear to be durable treatment option for single-sided deafness

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

Stematix enters into 10-year exclusive agreement with Laboratorios Bagó SA

Fast method for producing bone and cartilage tissue using body's own cells

Bacterin International completes $3M private placement of Secured Convertible Promissory Notes

Transition through hemogenic endothelial intermediate necessary for hematopoietic stem cell formation

Glycotex announces the expansion of patent portfolio in Advanced Wound Healing for GLYC-101

Better and standardized animal models needed for musculoskeletal regenerative medicine

Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

RTI Biologics supports Haiti relief efforts with Matrix HD sterilized dermis allografts donation

Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented

Fourth-quarter and full-year 2009 results announced by Quidel

Corgenix Medical files second-quarter Form 10-Q and reports financial results ended December 31, 2009

Daiichi Sankyo's Benicar receives FDA approval for hypertension treatment in children and adolescents aged 6-16

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Oral hygiene: Insights

Micromet outlines the design of registration study for blinatumomab in ALL

DMC recommends Gamida-Teva JV to continue enrollment in StemEx Phase III trial for leukemia and lymphoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News